学校法人順天堂　研究者情報データベース:::研究業績詳細:::

HOME　＞　研究業績詳細

研究業績詳細

服部信孝（ハットリノブタカ）

研究テーマ	神経学、神経変性疾患、遺伝性パーキンソン病神経疾患全般
研究業績（論文）	主な英文総説 1　Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease, Lancet, 2004, 364:722-724 2　Kubo S, Hattori N, Mizuno Y. Recessive Parkinson's disease, Mov Disord, 2006, 21:885-893 3　Kawajiri S, Saiki S, Sato S, Hattori N. Genetic mutations and functions of PINK1, Trends Pharmacol Sci, 2011, 32:573-580 4　Shimura H, Mizuno Y, Hattori N. Citation Classic Parkin and Parkinson Disease, Clin. Chem. 2012, 58:1260-1261 5　Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update, J Neurol Neurosurg Psychiatry, 2012, 83:430-436 6　Kubo S, Hattori N. Neurodegenerative disease, Can synucleinopathy and tauopathy be identified during life? ‎Nat. Rev. Neurol 2013, 9:426-427, 7　Hattori N. Movement disorders: advances in 2015, Lancet Neurol, 2016, 15:8-9, 8　Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE. Parkinson's disease in the Western Pacific Region. Lancet Neurol. 2019 Sep;18(9):865-879. 服部の研究にかかわる主な論文20報 1.Kitada, T, Asakawa, S, Hattori, N, Matsumine, H, Yamamura, Y, Minoshima, S, Yokochi, M, Mizuno, Y, and Shimizu, N.: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392;605-608, 1998. 2.Hattori, N, Kitada, T, Matsumine, H, Asakawa, S, Yamamura, Y, Yoshino, H, Kobayashi, T, Yokochi, M, Wang, M, Yoritaka, A, Kondo, T, Kuzuhara, S, Nakamura, S, Shimizu, N, and Mizuno, Y.: Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol., 44;935-941, 1998. 3.Shimura, H, Hattori, N, Kubo, S, Mizuno, Y, Asakawa, S, Minoshima, S, Shimizu, N, Iwai, K, Chiba, T, Tanaka, K, and Suzuki. T.: Familial Parkinson disease gene product parkin is a ubiquitin-protein ligase. Nature Genet., 25;302-305, 2000. 4.Hattori, N, and Mizuno, Y.: Pathogenetic mechanisms of parkin in Parkinson's disease. Review, Lancet, 364;722-4, 2004. 5.Matsuda, N, Sato, S, Shiba, K, Okatsu, K, Saisho, K, Gautier, CA, Sou, Y-S, Saiki, S, Kawajiri, S, Sato, F, Kimura, M, Komatsu, M, Hattori, N, and Tanaka, K.: PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol., 189;211-221, 2010. 6.Okatsu, K, Oka, T, Iguchi, M, Imamura, K, Kosako, H, Tani, N, Kimura, M, Go, E, Koyano, F, Funayama, M, Shiba-Fukushima, K, Sato, S, Shimizu, H, Fukunaga, Y, Taniguchi, H, Komatsu, M, Hattori, N, Mihara, K, Tanaka, K, and Matsuda, N.: PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria, Nature Commun., 3;1016, 2012. 7.Nishioka, K, Hayashi, S, Farrer, MJ, Singleton, AB, Yoshino, H, Imai, H, Kitami, T, Sato, K, Kuroda, R, Tomiyama, H, Mizoguchi, K, Murata, M, Toda, T, Imoto, I, Inazawa J, Mizuno, Y, and Hattori, N.: Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol., 59;298-309, 2006. 8.Shimura, H, Schlossmacher, MG, Hattori, N, Frosch, MP, Trockenbacher, A, Schneider, R, Mizuno, Y, Kosik, KS, and Selkoe, DJ.: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science, 293;263-269, 2001. 9.Funayama, M, Ohe, K, Amo, T, Furuya, N, Yamaguchi, J, Saiki, S, Li, Y, Ogaki, K, Ando, M, Yoshino, H, Tomiyama, H, Nishioka, K, Hasegawa, K, Saiki, H, Satake, W, Mogushi, K, Sasaki, R, Kokubo, Y, Kuzuhara, S, Toda, T, Mizuno, Y, Uchiyama, Y, Ohno, K, and Hattori, N.: CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol., 14;274-282, 2015. 10.Meng, H, Yamashita, C, Shiba-Fukushima, K, Inoshita, T, Funayama, M, Sato, S, Hatta, T, Natsume, T, Umitsu, M, Takagi, J, Imai, Y., and Hattori N.: Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nature Commun., 8;15500, 2017. 11.Oji, Y, Hatano, T, Ueno, SI, Funayama, M, Ishikawa, KI, Okuzumi, A, Noda, S, Sato, S, Satake, W, Toda, T, Li, Y, Hino-Takai, T, Kakuta, S, Tsunemi, T, Yoshino, H, Nishioka, K, Hattori, T, Mizutani, Y, Mutoh, T, Yokochi, F, Ichinose, Y, Koh, K, Shindo, K, Takiyama, Y, Hamaguchi, T, Yamada, M, Farrer, MJ, Uchiyama, Y, Akamatsu, W, Wu, YR, Matsuda, J, and Hattori, N,: Variants in saposin D domain of prosaposin gene linked to Parkinson's disease. Brain, 143;1190-1205, 2020. 12.Mori, A, Hatano, T, Inoshita, T, Shiba-Fukushima, K, Koinuma, T, Meng, H, Kubo, SI, Spratt, S, Cui, C, Yamashita, C, Miki, Y, Yamamoto, K, Hirabayashi, T, Murakami, M, Takahashi, Y, Shindou, H, Nonaka, T, Hasegawa, M, Okuzumi, A, Imai, Y, and Hattori N: Parkinson's disease- associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling. Proc. Natl. Acad. Sci. USA., 116;20689-20699, 2019. 13.Hattori, N, Tanaka, M, Ozawa, T, and Mizuno, Y.: Immunohistochemical studies on Complex-I Complex-II Complex-III and Complex-IV of mitochondria in Parkinsons-disease. Ann Neurol., 30;563-571, 1991. 14.Yoritaka, A, Hattori, N, Uchida, K, Tanaka, M, Stadtman, ER, and Mizuno, Y.: Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, Proc. Natl. Acad. Sci. USA., 93;2696- 2701, 1996. 15.Shimura-Miura, H, Hattori, N, Kang, D, Miyako, K, Nakabeppu, Y, and Mizuno, Y. : Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann Neurol., 46;920-4, 1999. 16.Satake, W, Nakabayashi, Y, Mizuta, I, Hirota, Y, Ito, C, Kubo, M, Kawaguchi, T, Tsunoda, T, Watanabe, M, Takeda, A, Tomiyama, H, Nakashima, K, Hasegawa, K, Obata, F, Yoshikawa, T, Kawakami, H, Sakoda, S, Yamamoto, M, Hattori, N, Murata, M, Nakamura, Y, and Toda, T.: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genet., 41;1303-7, 2009. 17.Hatano, T, Saiki, S, Hattori, N, Okuzumi, A, Mohney, RP, and Hattori, N.: Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry., 87;295-301, 2016. 18.Sasazawa, Y, Souma, S, Furuya, N, Miura, Y, Kazuno, S, Kakuta, S, Suzuki, A, Hashimoto, R, Hirawake-Mogi, H, Date, Y, Imoto, M, Ueno, T, Kataura, T, Korolchuk, VI, Tsunemi, T, Hattori, N, and Saiki, S.: Oxidative stress-induced phosphorylation of JIP4 regulates lysosomal positioning in coordination with TRPM--1166L1 and ALG2. EMBO J., 41;e111476, 2022. 19.Okuzumi, A, Kurosawa, M, Hatano, T, Takanashi, M, Nojiri, S, Fukuhara, T, Yamanaka, T, Miyazaki, H, Yoshinaga, S, Furukawa, Y, Shimogori, T, Hattori, N,* and Nukina, N.: Rapid　dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. Acta Neuropathol Commun., 6;96, 2018. 20.Okuzumi, A, Hatano, T, Matsumoto, G, Nojiri, S, Ueno, S-I, Imamichi-Tatano, Y, Kimura, H, Kakuta, S, Kondo, A, Fukuhara, T, Li, Y, Funayama, M, Saiki, S, Taniguchi, D, Tsunemi, T, McIntyre, D, Gérardy, J-J, Mittelbronn, M, Kruger, R, Uchiyama, Y, Nukina, N, and Hattori, N.: Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nature Med., 29;1448-1455, 2023. その他の主な英文原著 1　Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on Complex-I Complex-II Complex-III and Complex-IV of mitochondria in Parkinsons-disease, Ann Neurol, 1991, 30:563-571, 2　Mizuno Y, Matsuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-Ketoglutarate dehydrogenase complex in Parkinsons-disease, Ann Neurol, 1994, 35:204-210 3　Hattori N, Kitada T, Matsumine H, Mizuno Y, （15人中1番目）et al.; Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals, Ann Neurol, 1998, 44:935-941, 1998 4 Hattori N, Yoshino H, Tanaka M, Suzuki H, Mizuno Y. Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. Genomics. 1998 Apr 1;49(1):52-8. 　 5 Wang M, Hattori N, Shimizu N, Mizuno Y, et al; Polymorphism in the parkin gene in sporadic Parkinson's disease, Ann Neurol, 1999, 45:655-658, 6 Shimura H, Hattori N, Kubo S, Mizuno Y, et al; Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients, Ann Neurol, 1999, 45:668-672, 7 Ide T, Tsutsui H, Kinugawa S, Utsumi H, Hattori N, et al; Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium, Circ Res, 1999, 85:357-363, 8 Shimizu N, Hattori N, Shintani A, Kawasaki K, Kitada T, Minoshima S, Mizuno Y, Asakawa S. Sequencing analysis of deletion mutations in the giant Parkin gene. Am J Hum Genet, 1999, 65:4, A420, 9 Nisipeanu P, Inzelberg R, Hattori N, Mizuno Y, et al; Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: Mutation of Parkin gene, Neurology, 1999, 53:1602-1604, 10 Asakawa S, Hattori N, Mizuno Y, Shimizu N, et al; Molecular analysis of the deletion breakpoints of Parkin gene. Am J Hum Genet, 2000, 67:398-398, 11 Lu CS, Wu JC, Hattori N, Yoshino H, Mizuno Y, et al; Clinical and genetic studies on familial parkinsonism: The first report on a parkin gene mutation in a Taiwanese family, ‎Mov Disord, 2001, 16:164-166, 12 Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin gene mutation in a Korean woman, Arch Neurol, 2001, 58:988-989, 13 Nisipeanu P, Inzelberg, R, Hattori N, Mizuno Y, et al; Parkin gene causing benign autosomal recessive juvenile parkinsonism, Neurology, 2001, 56:1573-1575, 14 Imai Y, Soda M, Hattori N, Takahashi R, et al; An unfolded putative transmembrane polypeptide which can lead to endoplasmic reticulum stress is a substrate of parkin, Cell, 2001, 105:891-902, 15 Momose Y, Murata M, Hattori N, Toda T, et al; Association studies of multiple candidate genes for Parkinson's disease by using single nucleotide polymorphisms. Am J Hum Genet, 2001, 69:499-499, 16 Kobayashi H, Kruger R, Hattori N, et al; Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease, BRAIN, 2003, 126:32-42, 17 Sakata E, Hattori N, Kato K. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain, EMBO REPORTS, 2003, 4:301-306, 18 Rawal N, Periquet M, Hattori N, Brice A, et al;. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism, French Parkinsons's Dis Genetics S; European Consortium Genetic Sus, Neurology, 2003, 60:1378-1381, 19 Inzelberg, R, Hattori N, Mizuno Y, et al; Camptocormia axial dystonia and parkinsonism: Phenotypic heterogeneity of a parkin mutation, Neurology, 2003, 60:1393-1394, 20 Hirota Y, Momose Y, Hattori N, Inoko H, Toda T. Genome-wide microsatellite association studies for Parkinson's disease by using the pooled DNA method. Am J Hum Genet, 2003, 73:469, Annual Meeting of the American-Society-of-Human-Genetics, NOV 04-08, 2003, 21 Maraganore DM, Lesnick, TG, Hattori N, Rocca WA, et al; UCHL1 is a Parkinson's disease susceptibility gene UCHL1 Global Genetics Consortium, Ann Neurol, 2004, 55:512-521, 22 Tanaka M, Cabrera VM, Hattori N, Shimodaira H, et al; Mitochondrial genome variation in Eastern Asia and the peopling of Japan, Genome Res, 2004, 14:10A;1832-1850, 23 Moore DJ, Zhang L, Hattori N, Dawson VL, et al;.Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress, Hum Mol Gen, 2005, 14:71-84, 24 Fukae J, Takanashi M, Hattori N, et al; Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders, Acta Neuropathol, 2005, 109:256-262, 25 Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease, Neurology, 2005, 64:1081-1083, 26 Li Y, Tomiyama H, Hattori N, et al; Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism, Neurology, 2005, 64:1955-1957, 27 Orimo S, Amino T, Hattori N, Mizuno Y, et al; Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2, Mov Disord, 2005, 20:1350-1353, 28 Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K. 14-3-3 eta is a novel regulator of parkin ubiquitin ligase, EMBO JOURNAL, 2006, 25:211-221, 29 Mizuta I, Satake W, Hattori N, Toda T, et al; Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease, Hum Mol Gen, 2006, 15:1151-1158, 30 Akagawa M, Ito S, Hattori N, Matsuda T, Uchida K, et al; Bispecific Abs against modified protein and DNA with oxidized lipids, PNAS, 2006, 103:6160-6165, 31 Arai T, Fukae J, Hattori N, et al; Up-regulation of hMUTYH, a DNA repair enzyme in the mitochondria of substantia nigra in Parkinson's disease, Acta Neuropathol, 2006, 112:139-145, 32 Tomiyama H, Li Y, Hattori N, et al; Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries, Mov Disord, 2006, 21:1102-1108, 33 Maraganore DM, de Andrade M, Hattori N, et al., Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA, 2006, 296:661-70, 34 Sato K, Hatano T, Hattori N, Mizuno Y, et al; Prognosis of Parkinson's disease: Time to stage IIi IV, V, and to motor fluctuations, Juntendo Parkinson Study Grp, Mov Disord, 2006, 21:1384-1395, 35 Ihara M, Yamasaki N, Hattori N, Kinoshita M, et al; Sept4, a component of presynaptic scaffold and Lewy bodies is required for the suppression of alpha-synuclein neurotoxicity. NEURON, 2007, 53:519-533, 36 Hatano T, Kubo S, Hattori N, et al; Leucine-rich repeat kinase 2 associates with lipid rafts, Hum Mol Gen, 2007, 16:678-690, 37 Saiki S, Sakai K, Hattori N, Hirose G, et al; Primary skeletal muscle involvement in chorea-acanthocytosis, Mov Disord, 2007, 22:848-852, 38 Saiki M, Saiki S, Hattori N, Hirose G, et al; Neurological deficits are associated with increased brain calcinosis hypoperfusion and hypometabolism in idiopathic basal ganglia calcification, ‎Mov Disord, 2007, 22:1027-1030, 39 Obi T, Nishioka K, Hattori N, et al; Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia, Neurology, 2008, 70:238-241, 40 Ning YP, Kanai K., Hattori N, et al; PARK9-linked parkinsonism in eastern Asia: Mutation detection in ATP13A2 and clinical phenotype, Neurology, 2008, 70:1491-1493, 41 Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008, 63:743-50, 42 Kumazawa R, Tomiyama H, Li Y, Hattori N, et al; Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease, Arch Neurol, 2008, 65:802-808, 43 Mizuno Y, Hattori N, Kubo S, Mochizuki H, et al; Progress in the pathogenesis and genetics of Parkinson's disease, Philos Trans R Soc Lond B Biol Sci, 2008, 363:2215-2227, 44 Ross OA, Wu YR, Lee MC, Hattori N, Tan EK, Wu RM, et al; Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol. 2008, 64:88-92, 45 Kanai K, Asahina M, Hattori N, Hattori T, et al; Preserved Cardiac I-123-MIBG Uptake and Lack of Severe Autonomic Dysfunction in a PARK9 Patient. ‎Mov Disord, 2009, 24:1403-1405, 46 Nishioka K, Ross OA., Farrer MJ, Hattori N, et al; Expanding the Clinical Phenotype of SNCA Duplication Carriers, Mov Disord, 2009, 24:1811-1819, 47 Mitsui J, Takahashi Y, Hattori N, Tsuji S, et al; Mechanisms of Genomic Instabilities Underlying Two Common Fragile-Site-Associated Loci PARK2 and DMD, in Germ Cell and Cancer Cell Lines, Am J Hum Genet, 2010, 87:75-89, 48 Yoshino H, Tomiyama H, Hattori N, et al; Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism, Neurology, 2010, 75:1356-1361, 49 Funayama M, Tomiyama H, Hattori N, et al; Rapid Screening of ATP13A2 Variant with High-Resolution Melting Analysis, ‎Mov Disord, 2010, 25:2434-37, 50 Saiki S, Sasazawa Y, Hattori N, et al; Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition, Autophagy, 2011, 7:176-187, 51 Ogaki K, Motoi Y, Li Y, Hattori N, et al; Visual Grasping in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (Microtubule-Associated with Protein Tau): A Comparison of N-Isopropyl-p-[I-123]-iodoamphetamine Brain Perfusion Single Photon Emission Computed Tomography Analysis with Progressive Supranuclear Palsy. ‎Mov Disord, 2011, 26:561-563, 52 Ross OA, Soto-Ortolaza AI, Hattori N, Farrer MJ, et al; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908, 53 Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, Hattori N. PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy, Sci Rep, 2012, 2:1002, 54 Liu S, Sawada T, Hattori N, Imai Y, Lu B, et al; Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet, 2012, 8:e1002537. 55 Funayama M, Yoshino H, Li Y, Kusaka H, Tomiyama H, Hattori N. Pseudo-heterozygous rearrangement mutation of parkin, ‎Mov Disord, 2012, 27:552-555, 55 Sharma M, Ioannidis JP, Hattori N, Krüger R, et al; GEO-PD Consortium. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012, 79:659-67, 56 Ando M, Funayama M, Li Y, Hattori N, et al; VPS35 mutation in Japanese patients with typical Parkinson's disease, ‎Mov Disord, 2012, 27:1413-1417, 57 Hattori N., Hasegawa K., Sakamoto T. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease, J Clin Pharm Ther, 2012, 37:571-577, 58 Sharma M, Ioannidis JP, Hattori N, Krüger R, et al; GEOPD consortium. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet. 2012, 49:721-6. 59 Itokawa K, Sekine T, Hattori N, Araki N, et al; A case of alpha-synuclein gene duplication presenting with head-shaking movements, ‎Mov Disord, 2013, 28:384-387, 60 Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S. Hattori N. Pilot study of H-2 therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial, Mov Disord, 2013, 28:836-839, 61 Mizuno Y, Nomoto M, Hattori N, et al; Transdermal Rotigotine in Early Stage Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Trial, Rotigotine Trial Grp, Mov Disord, 2013, 28:1447-1450, 62 Heckman MG, Soto-Ortolaza AI, Hattori N, Ross OA, et al; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease, Mov Disord. 2013, 28:1740-4. 63 Yamanaka T. Tosaki A, Hattori N, Nukina N, et al; NF-Y inactivation causes atypical neurodegeneration characterized by ubiquitin and p62 accumulation and endoplasmic reticulum disorganization, Nat. Commun, 2014, 5:3354, 64 Miyazaki H, Oyama F, Hattori N, Nukina N, et al; Singular localization of sodium channel beta 4 subunit in unmyelinated fibres and its role in the striatum, Nat Commun. 2014, 5:5525, 65 Hattori N. Cerebral organoids model human brain development and microcephaly, Mov Disord, 2014, 29:185-185, 66 Furuya N, Ikeda SI, Sato S, Hattori N, Ueno T, et al; PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation, Autophagy, 2014, 10:631-641, 67 Okuzumi A, Hatano T, Nakahara T, Yokoyama K, Hattori N. Ophthalmic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy, Neurology, 2014, 82:1566-1567, 68 Hattori N. REST as a New Therapeutic Target for Neurodegenerative Disorders, Mov Disord, 2014, 29:869-869, 69 Maraschi A, Ciammola A, Sato S, Hattori N, Sassone J, et al; Parkin regulates kainate receptors by interacting with the GluK2 subunit. Nat Commun, 2014, 5:5182. 70 Kurosawa M, Matsumoto G, Hattori N, Nukina N, et al; Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice, Hum Mol Gen, 2015, 24:1092-1105, 71 Matsuo H, Tomiyama H, Hattori N, Shinomiya N, et al; ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout, Ann Clin Transl Neurol, 2015, 2:302-306, 72 Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015, 2:417-26. 73 Matsumoto G, Shimogori T, Hattori N, Nukina N. TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation, Hum Mol Gen, 2015, 24:4429-4442, 74 Imai Y, Kobayashi Y, Nukina N. Hattori N, Takahashi R, et al; The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway, PLoS Genet, 2015,11:e1005503, 75 Wang L, Aasly JO, Hattori N, Sharma M, et al; GEO-PD Consortium. Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85:1283-1292, 76 Ogaki K, Koga S, Hattori N, Ross OA, et al; Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders, Neurology, 2015, 85:2016-25, 77 Hatano T, Kurita N, Kobayashi M, Hattori N. Teaching Video NeuroImages: Re-emergent jaw tremor in Parkinson disease. Neurology, 2015, 85:e181, 78 Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation, Neurology, 2016, 86:2212-2213, 79 Kamagata K, Hatano T, Okuzumi A, Motoi Y, Abe O, Shimoji K, Kamiya K, Suzuki M, Hori M, Kumamaru K, Hattori N, Aoki S. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease, Euro Radiol, 2016, 26:2567-2577, 80 Sato S, Koike M, Funayama M, Ezaki J, Fukuda T, Ueno T, Uchiyama Y, Hattori N. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice, Am J Pathol, 2016, 186:3074-3082, 81 Matsushima T, Conedera S, Tanaka R, Li Y, Yoshino H, Funayama M, Ikeda A, Hosaka Y, Okuzumi A, Shimada Y, Yamashiro K, Motoi Y, Nishioka K, Hattori N. Genotype-phenotype correlations of cysteine replacement in CADASIL, Neurobiol. Aging, 2017, 50:169.e7, 81 Inoshita T, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, Morimoto T, Koike M, Chang H-Y, Imai Y, Hattori N. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila, Hum Mol Genet, 2017, 26:2933-2948, 82 Shiba-Fukushima K, Ishikawa KI, Inoshita T, Izawa N, Takanashi M, Sato S, Onodera O, Akamatsu W, Okano H, Imai Y, Hattori N. Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease. Hum Mol Genet. 2017, 26(16):3172-3185. 83 Saiki S, Hatano T, Fujimaki M, Ishikawa KI, Mori A, Oji Y, Okuzumi A, Fukuhara T, Koinuma T, Imamichi Y, Nagumo M, Furuya N, Nojiri S, Amo T, Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Sci Rep. 2017 Aug 4;7(1):7328.　 84 Hattori N, Arano T, Hatano T, Mori A, Imai Y. Mitochondrial-Associated Membranes in Parkinson's Disease. Adv Exp Med Biol. 2017;997:157-169. 85 Hattori N, Mizuno Y. Twenty years since the discovery of the parkin gene. J Neural Transm (Vienna). 2017 Sep; 124(9):1037-1054 86 Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa KI, Kobayashi K, Murayama S, Hwang SH, Saiki S, Akamatsu W, Hattori N, Hammock BD, Hashimoto K. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5815-E5823. 87 Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease. Mov Disord. 2018 Sep;33(9):1488-1492. 88 Yoritaka A, Ohtsuka C, Maeda T, Hirayama M, Abe T, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Oda E, Ito M, Ohno K, Hattori N. Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease. Mov Disord. 2018 Sep;33(9):1505-1507. 89 Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018 Jan 30;90(5):e404-e411. 90 Mishima T, Fujioka S, Tomiyama H, Yabe I, Kurisaki R, Fujii N, Neshige R, Ross OA, Farrer MJ, Dickson DW, Wszolek ZK, Hattori N, Tsuboi Y. Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry. 2018 May;89(5):482-487. 91 Takanashi M, Funayama M, Matsuura E, Yoshino H, Li Y, Tsuyama S, Takashima H, Nishioka K, Hattori N. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathol Commun. 2018 Oct 17;6(1):105. 92 Sato S, Uchihara T, Fukuda T, Noda S, Kondo H, Saiki S, Komatsu M, Uchiyama Y, Tanaka K, Hattori N. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice. Sci Rep. 2018 Feb 12;8(1):2813. 93 Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29;8(1). pii: E14. 94 Ikeda A, Shimada H, Nishioka K, Takanashi M, Hayashida A, Li Y, Yoshino H, Funayama M, Ueno Y, Hatano T, Sahara N, Suhara T, Higuchi M, Hattori N. Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features. Mov Disord. 2019 Apr;34(4):568-574. 95 Okuzumi A, Hatano T, Kamagata K, Hori M, Mori A, Oji Y, Taniguchi D, Daida K, Shimo Y, Yanagisawa N, Nojiri S, Aoki S, Hattori N. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease? Eur J Neurol. 2019 Nov;26(11):1408-1416. 96 Imai Y, Inoshita T, Meng H, Shiba-Fukushima K, Hara KY, Sawamura N, Hattori N. Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson's disease. Commun Biol. 2019 Nov 22;2:424, 97 Ikeda A, Nishioka K, Meng H, Takanashi M, Hasegawa I, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yamaguchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N. Mutations in CHCHD2 cause α-synuclein aggregation. Hum Mol Genet. 2019 Dec 1;28(23):3895-3911. 98 Ogawa T, Hatano T, Oyama G, Takanashi M, Taniguchi D, Hattori N. Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules. Mov Disord Clin Pract. 2020 Jan 20;7(2):240-242. 99 Miyamoto N, Magami S, Inaba T, Ueno Y, Hira K, Kijima C, Nakajima S, Yamashiro K, Urabe T, Hattori N. The effects of A1/A2 astrocytes on oligodendrocyte linage cells against white matter injury under prolonged cerebral hypoperfusion. Glia. 2020 Sep;68(9):1910-1924. 100 Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease. Mov Disord. 2020 Sep;35(9):1565-1573. 101 Li Y, Ikeda A, Yoshino H, Oyama G, Kitani M, Daida K, Hayashida A, Ogaki K, Yoshida K, Kimura T, Nakayama Y, Ito H, Sugeno N, Aoki M, Miyajima H, Kimura K, Ueda N, Watanabe M, Urabe T, Takanashi M, Funayama M, Nishioka K, Hattori N. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. J Hum Genet. 2020 Sep;65(9):771-781. 102 Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N. Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord. 2020 Aug;35(8):1438-1447. 103 Hattori N, Kitabayashi H, Kanda T, Nomura T, Toyama K, Mori A. A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease. Mov Disord. 2020 Aug;35(8):1481-1487, 104 Daida K, Nishioka K, Li Y, Yoshino H, Shimada T, Dougu N, Nakatsuji Y, Ohara S, Hashimoto T, Okiyama R, Yokochi F, Suzuki C, Tomiyama M, Kimura K, Ueda N, Tanaka F, Yamada H, Fujioka S, Tsuboi Y, Uozumi T, Takei T, Matsuzaki S, Shibasaki M, Kashihara K, Kurisaki R, Yamashita T, Fujita N, Hirata Y, Ii Y, Wada C, Eura N, Sugie K, Higuchi Y, Kojima F, Imai H, Noda K, Shimo Y, Funayama M, Hattori N. PLA2G6 variants associated with the number of affected alleles in Parkinson's disease in Japan. Neurobiol Aging. 2021 Jan;97:147.e1-147.e9. 105 Andica C, Kamagata K, Saito Y, Uchida W, Fujita S, Hagiwara A, Akashi T, Wada A, Ogawa T, Hatano T, Hattori N, Aoki S. Fiber-specific white matter alterations in early-stage tremor-dominant Parkinson's disease. NPJ Parkinsons Dis. 2021 Jun 25;7(1):51. 106 Elahi M, Motoi Y, Shimonaka S, Ishida Y, Hioki H, Takanashi M, Ishiguro K, Imai Y, Hattori N. High-fat diet-induced activation of SGK1 promotes Alzheimer's disease-associated tau pathology. Hum Mol Genet. 2021 Aug 28;30(18):1693-1710. 107 Kataura T, Tashiro E, Nishikawa S, Shibahara K, Muraoka Y, Miura M, Sakai S, Katoh N, Totsuka M, Onodera M, Shin-Ya K, Miyamoto K, Sasazawa Y, Hattori N, Saiki S, Imoto M. A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers. Autophagy. 2021 Aug;17(8):1856-1872. 108 Okuzumi A, Hatano T, Fukuhara T, Ueno S, Nukina N, Imai Y, Hattori N. α-Synuclein Seeding Assay Using RT-QuIC. Methods Mol Biol. 2021;2322:3-16. 109 Tsunemi T, Ishiguro Y, Yoroisaka A, Hattori N. Analysis of α-Synuclein in Exosomes. Methods Mol Biol. 2021;2322:41-45. Tsunemi T, Oyama G, Saiki S, Hatano T, Fukae J, Shimo Y, Hattori N. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review. Mov Disord. 2021 Aug;36(8):1759-1771. 110 --

研究テーマ

神経学、神経変性疾患、遺伝性パーキンソン病神経疾患全般

研究業績（論文）

主な英文総説
1　Hattori N, Mizuno Y. Pathogenetic mechanisms of parkin in Parkinson's disease, Lancet, 2004, 364:722-724

2　Kubo S, Hattori N, Mizuno Y. Recessive Parkinson's disease, Mov Disord, 2006, 21:885-893

3　Kawajiri S, Saiki S, Sato S, Hattori N. Genetic mutations and functions of PINK1, Trends Pharmacol Sci, 2011, 32:573-580

4　Shimura H, Mizuno Y, Hattori N. Citation Classic Parkin and Parkinson Disease, Clin. Chem. 2012, 58:1260-1261

5　Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update, J Neurol Neurosurg Psychiatry, 2012, 83:430-436
6　Kubo S, Hattori N. Neurodegenerative disease, Can synucleinopathy and tauopathy be identified during life? ‎Nat. Rev. Neurol 2013, 9:426-427,
7　Hattori N. Movement disorders: advances in 2015, Lancet Neurol, 2016, 15:8-9,
8　Lim SY, Tan AH, Ahmad-Annuar A, Klein C, Tan LCS, Rosales RL, Bhidayasiri R, Wu YR, Shang HF, Evans AH, Pal PK, Hattori N, Tan CT, Jeon B, Tan EK, Lang AE. Parkinson's disease in the Western Pacific Region. Lancet Neurol. 2019 Sep;18(9):865-879.

服部の研究にかかわる主な論文20報

1.Kitada, T, Asakawa, S, Hattori, N, Matsumine, H, Yamamura, Y, Minoshima, S, Yokochi, M, Mizuno, Y, and Shimizu, N.*: Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism, Nature, 392;605-608, 1998.

2.Hattori, N*, Kitada, T, Matsumine, H, Asakawa, S, Yamamura, Y, Yoshino, H, Kobayashi, T, Yokochi, M, Wang, M, Yoritaka, A, Kondo, T, Kuzuhara, S, Nakamura, S, Shimizu, N, and Mizuno, Y.*: Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol., 44;935-941, 1998.

3.Shimura, H, Hattori, N, Kubo, S, Mizuno, Y, Asakawa, S, Minoshima, S, Shimizu, N, Iwai, K, Chiba, T, Tanaka, K*, and Suzuki. T.: Familial Parkinson disease gene product parkin is a ubiquitin-protein ligase. Nature Genet., 25;302-305, 2000.

4.Hattori, N*, and Mizuno, Y.: Pathogenetic mechanisms of parkin in Parkinson's disease. Review, Lancet, 364;722-4, 2004.

5.Matsuda, N, Sato, S, Shiba, K, Okatsu, K, Saisho, K, Gautier, CA, Sou, Y-S, Saiki, S, Kawajiri, S, Sato, F, Kimura, M, Komatsu, M, Hattori, N, and Tanaka, K.*: PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol., 189;211-221, 2010.

6.Okatsu, K, Oka, T, Iguchi, M, Imamura, K, Kosako, H, Tani, N, Kimura, M, Go, E, Koyano, F, Funayama, M, Shiba-Fukushima, K, Sato, S, Shimizu, H, Fukunaga, Y, Taniguchi, H, Komatsu, M, Hattori, N, Mihara, K, Tanaka, K, and Matsuda, N.*: PINK1 autophosphorylation upon membrane potential dissipation is essential for Parkin recruitment to damaged mitochondria, Nature Commun., 3;1016, 2012.

7.Nishioka, K, Hayashi, S, Farrer, MJ, Singleton, AB, Yoshino, H, Imai, H, Kitami, T, Sato, K, Kuroda, R, Tomiyama, H, Mizoguchi, K, Murata, M, Toda, T, Imoto, I, Inazawa J, Mizuno, Y, and Hattori, N.*: Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol., 59;298-309, 2006.

8.Shimura, H, Schlossmacher, MG, Hattori, N, Frosch, MP, Trockenbacher, A, Schneider, R, Mizuno, Y, Kosik, KS, and Selkoe, DJ.: Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science, 293;263-269, 2001.

9.Funayama, M, Ohe, K, Amo, T, Furuya, N, Yamaguchi, J, Saiki, S, Li, Y, Ogaki, K, Ando, M, Yoshino, H, Tomiyama, H, Nishioka, K, Hasegawa, K, Saiki, H, Satake, W, Mogushi, K, Sasaki, R, Kokubo, Y, Kuzuhara, S, Toda, T, Mizuno, Y, Uchiyama, Y, Ohno, K, and Hattori, N.*: CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study. Lancet Neurol., 14;274-282, 2015.

10.Meng, H, Yamashita, C, Shiba-Fukushima, K, Inoshita, T, Funayama, M, Sato, S, Hatta, T, Natsume, T, Umitsu, M, Takagi, J, Imai, Y.*, and Hattori N.*: Loss of Parkinson's disease-associated protein CHCHD2 affects mitochondrial crista structure and destabilizes cytochrome c. Nature Commun., 8;15500, 2017.

11.Oji, Y, Hatano, T, Ueno, SI, Funayama, M, Ishikawa, KI, Okuzumi, A, Noda, S, Sato, S, Satake, W, Toda, T, Li, Y, Hino-Takai, T, Kakuta, S, Tsunemi, T, Yoshino, H, Nishioka, K, Hattori, T, Mizutani, Y, Mutoh, T, Yokochi, F, Ichinose, Y, Koh, K, Shindo, K, Takiyama, Y, Hamaguchi, T, Yamada, M, Farrer, MJ, Uchiyama, Y, Akamatsu, W, Wu, YR, Matsuda, J, and Hattori, N,*: Variants in saposin D domain of prosaposin gene linked to Parkinson's disease. Brain, 143;1190-1205, 2020.

12.Mori, A, Hatano, T, Inoshita, T, Shiba-Fukushima, K, Koinuma, T, Meng, H, Kubo, SI, Spratt, S, Cui, C, Yamashita, C, Miki, Y, Yamamoto, K, Hirabayashi, T, Murakami, M, Takahashi, Y, Shindou, H, Nonaka, T, Hasegawa, M, Okuzumi, A, Imai, Y, and Hattori N*: Parkinson's disease- associated iPLA2-VIA/PLA2G6 regulates neuronal functions and α-synuclein stability through membrane remodeling. Proc. Natl. Acad. Sci. USA., 116;20689-20699, 2019.

13.Hattori, N, Tanaka, M, Ozawa, T, and Mizuno, Y.*: Immunohistochemical studies on Complex-I Complex-II Complex-III and Complex-IV of mitochondria in Parkinsons-disease. Ann Neurol., 30;563-571, 1991.

14.Yoritaka, A, Hattori, N, Uchida, K, Tanaka, M, Stadtman, ER, and Mizuno, Y.: Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease, Proc. Natl. Acad. Sci. USA., 93;2696- 2701, 1996.

15.Shimura-Miura, H, Hattori, N, Kang, D, Miyako, K, Nakabeppu, Y, and Mizuno, Y. : Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann Neurol., 46;920-4, 1999.

16.Satake, W, Nakabayashi, Y, Mizuta, I, Hirota, Y, Ito, C, Kubo, M, Kawaguchi, T, Tsunoda, T, Watanabe, M, Takeda, A, Tomiyama, H, Nakashima, K, Hasegawa, K, Obata, F, Yoshikawa, T, Kawakami, H, Sakoda, S, Yamamoto, M, Hattori, N, Murata, M, Nakamura, Y, and Toda, T.*: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genet., 41;1303-7, 2009.

17.Hatano, T, Saiki, S, Hattori, N, Okuzumi, A, Mohney, RP, and Hattori, N*.: Identification of novel biomarkers for Parkinson's disease by metabolomic technologies. J Neurol Neurosurg Psychiatry., 87;295-301, 2016.

18.Sasazawa, Y, Souma, S, Furuya, N, Miura, Y, Kazuno, S, Kakuta, S, Suzuki, A, Hashimoto, R, Hirawake-Mogi, H, Date, Y, Imoto, M, Ueno, T, Kataura, T, Korolchuk, VI, Tsunemi, T, Hattori, N*, and Saiki, S.*: Oxidative stress-induced phosphorylation of JIP4 regulates lysosomal positioning in coordination with TRPM--1166L1 and ALG2. EMBO J., 41;e111476, 2022.

19.Okuzumi, A, Kurosawa, M, Hatano, T, Takanashi, M, Nojiri, S, Fukuhara, T, Yamanaka, T, Miyazaki, H, Yoshinaga, S, Furukawa, Y, Shimogori, T, Hattori, N,* and Nukina, N*.: Rapid　dissemination of alpha-synuclein seeds through neural circuits in an in-vivo prion-like seeding experiment. Acta Neuropathol Commun., 6;96, 2018.

20.Okuzumi, A, Hatano, T, Matsumoto, G, Nojiri, S, Ueno, S-I, Imamichi-Tatano, Y, Kimura, H, Kakuta, S, Kondo, A, Fukuhara, T, Li, Y, Funayama, M, Saiki, S, Taniguchi, D, Tsunemi, T, McIntyre, D, Gérardy, J-J, Mittelbronn, M, Kruger, R, Uchiyama, Y, Nukina, N, and Hattori, N.*: Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. Nature Med., 29;1448-1455, 2023.

その他の主な英文原著
1　Hattori N, Tanaka M, Ozawa T, Mizuno Y. Immunohistochemical studies on Complex-I Complex-II Complex-III and Complex-IV of mitochondria in Parkinsons-disease, Ann Neurol, 1991, 30:563-571,

2　Mizuno Y, Matsuda S, Yoshino H, Mori H, Hattori N, Ikebe S. An immunohistochemical study on alpha-Ketoglutarate dehydrogenase complex in Parkinsons-disease, Ann Neurol, 1994, 35:204-210

3　Hattori N, Kitada T, Matsumine H, Mizuno Y, （15人中1番目）et al.; Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: Evidence for variable homozygous deletions in the Parkin gene in affected individuals, Ann Neurol, 1998, 44:935-941, 1998

4 Hattori N, Yoshino H, Tanaka M, Suzuki H, Mizuno Y. Genotype in the 24-kDa subunit gene (NDUFV2) of mitochondrial complex I and susceptibility to Parkinson disease. Genomics. 1998 Apr 1;49(1):52-8. 　

5 Wang M, Hattori N, Shimizu N, Mizuno Y, et al; Polymorphism in the parkin gene in sporadic Parkinson's disease, Ann Neurol, 1999, 45:655-658,

6 Shimura H, Hattori N, Kubo S, Mizuno Y, et al; Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients, Ann Neurol, 1999, 45:668-672,

7 Ide T, Tsutsui H, Kinugawa S, Utsumi H, Hattori N, et al; Takeshita A. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium, Circ Res, 1999, 85:357-363,

8 Shimizu N, Hattori N, Shintani A, Kawasaki K, Kitada T, Minoshima S, Mizuno Y, Asakawa S. Sequencing analysis of deletion mutations in the giant Parkin gene. Am J Hum Genet, 1999, 65:4, A420,

9 Nisipeanu P, Inzelberg R, Hattori N, Mizuno Y, et al; Autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: Mutation of Parkin gene, Neurology, 1999, 53:1602-1604,

10 Asakawa S, Hattori N, Mizuno Y, Shimizu N, et al; Molecular analysis of the deletion breakpoints of Parkin gene. Am J Hum Genet, 2000, 67:398-398,

11 Lu CS, Wu JC, Hattori N, Yoshino H, Mizuno Y, et al; Clinical and genetic studies on familial parkinsonism: The first report on a parkin gene mutation in a Taiwanese family, ‎Mov Disord, 2001, 16:164-166,

12 Jeon BS, Kim JM, Lee DS, Hattori N, Mizuno Y. An apparently sporadic case with parkin gene mutation in a Korean woman, Arch Neurol, 2001, 58:988-989,

13 Nisipeanu P, Inzelberg, R, Hattori N, Mizuno Y, et al; Parkin gene causing benign autosomal recessive juvenile parkinsonism, Neurology, 2001, 56:1573-1575,

14 Imai Y, Soda M, Hattori N, Takahashi R, et al; An unfolded putative transmembrane polypeptide which can lead to endoplasmic reticulum stress is a substrate of parkin, Cell, 2001, 105:891-902,

15 Momose Y, Murata M, Hattori N, Toda T, et al; Association studies of multiple candidate genes for Parkinson's disease by using single nucleotide polymorphisms. Am J Hum Genet, 2001, 69:499-499,

16 Kobayashi H, Kruger R, Hattori N, et al; Haploinsufficiency at the alpha-synuclein gene underlies phenotypic severity in familial Parkinson's disease, BRAIN, 2003, 126:32-42,

17 Sakata E, Hattori N, Kato K. Parkin binds the Rpn10 subunit of 26S proteasomes through its ubiquitin-like domain, EMBO REPORTS, 2003, 4:301-306,

18 Rawal N, Periquet M, Hattori N, Brice A, et al;. New parkin mutations and atypical phenotypes in families with autosomal recessive parkinsonism, French Parkinsons's Dis Genetics S; European Consortium Genetic Sus, Neurology, 2003, 60:1378-1381,

19 Inzelberg, R, Hattori N, Mizuno Y, et al; Camptocormia axial dystonia and parkinsonism: Phenotypic heterogeneity of a parkin mutation, Neurology, 2003, 60:1393-1394,

20 Hirota Y, Momose Y, Hattori N, Inoko H, Toda T. Genome-wide microsatellite association studies for Parkinson's disease by using the pooled DNA method. Am J Hum Genet, 2003, 73:469, Annual Meeting of the American-Society-of-Human-Genetics, NOV 04-08, 2003,

21 Maraganore DM, Lesnick, TG, Hattori N, Rocca WA, et al; UCHL1 is a Parkinson's disease susceptibility gene UCHL1 Global Genetics Consortium, Ann Neurol, 2004, 55:512-521,

22 Tanaka M, Cabrera VM, Hattori N, Shimodaira H, et al; Mitochondrial genome variation in Eastern Asia and the peopling of Japan, Genome Res, 2004, 14:10A;1832-1850,

23 Moore DJ, Zhang L, Hattori N, Dawson VL, et al;.Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress, Hum Mol Gen, 2005, 14:71-84,

24 Fukae J, Takanashi M, Hattori N, et al; Expression of 8-oxoguanine DNA glycosylase (OGG1) in Parkinson's disease and related neurodegenerative disorders, Acta Neuropathol, 2005, 109:256-262,

25 Sato S, Mizuno Y, Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease, Neurology, 2005, 64:1081-1083,

26 Li Y, Tomiyama H, Hattori N, et al; Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism, Neurology, 2005, 64:1955-1957,

27 Orimo S, Amino T, Hattori N, Mizuno Y, et al; Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2, Mov Disord, 2005, 20:1350-1353,

28 Sato S, Chiba T, Sakata E, Kato K, Mizuno Y, Hattori N, Tanaka K. 14-3-3 eta is a novel regulator of parkin ubiquitin ligase, EMBO JOURNAL, 2006, 25:211-221,

29 Mizuta I, Satake W, Hattori N, Toda T, et al; Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease, Hum Mol Gen, 2006, 15:1151-1158,

30 Akagawa M, Ito S, Hattori N, Matsuda T, Uchida K, et al; Bispecific Abs against modified protein and DNA with oxidized lipids, PNAS, 2006, 103:6160-6165,

31 Arai T, Fukae J, Hattori N, et al; Up-regulation of hMUTYH, a DNA repair enzyme in the mitochondria of substantia nigra in Parkinson's disease, Acta Neuropathol, 2006, 112:139-145,

32 Tomiyama H, Li Y, Hattori N, et al; Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson's disease patients from 18 countries, Mov Disord, 2006, 21:1102-1108,

33 Maraganore DM, de Andrade M, Hattori N, et al., Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA, 2006, 296:661-70,

34 Sato K, Hatano T, Hattori N, Mizuno Y, et al; Prognosis of Parkinson's disease: Time to stage IIi IV, V, and to motor fluctuations, Juntendo Parkinson Study Grp, Mov Disord, 2006, 21:1384-1395,

35 Ihara M, Yamasaki N, Hattori N, Kinoshita M, et al; Sept4, a component of presynaptic scaffold and Lewy bodies is required for the suppression of alpha-synuclein neurotoxicity. NEURON, 2007, 53:519-533,

36 Hatano T, Kubo S, Hattori N, et al; Leucine-rich repeat kinase 2 associates with lipid rafts, Hum Mol Gen, 2007, 16:678-690,

37 Saiki S, Sakai K, Hattori N, Hirose G, et al; Primary skeletal muscle involvement in chorea-acanthocytosis, Mov Disord, 2007, 22:848-852,

38 Saiki M, Saiki S, Hattori N, Hirose G, et al; Neurological deficits are associated with increased brain calcinosis hypoperfusion and hypometabolism in idiopathic basal ganglia calcification, ‎Mov Disord, 2007, 22:1027-1030,

39 Obi T, Nishioka K, Hattori N, et al; Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia, Neurology, 2008, 70:238-241,

40 Ning YP, Kanai K., Hattori N, et al; PARK9-linked parkinsonism in eastern Asia: Mutation detection in ATP13A2 and clinical phenotype, Neurology, 2008, 70:1491-1493,

41 Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol. 2008, 63:743-50,

42 Kumazawa R, Tomiyama H, Li Y, Hattori N, et al; Mutation analysis of the PINK1 gene in 391 patients with Parkinson disease, Arch Neurol, 2008, 65:802-808,

43 Mizuno Y, Hattori N, Kubo S, Mochizuki H, et al; Progress in the pathogenesis and genetics of Parkinson's disease, Philos Trans R Soc Lond B Biol Sci, 2008, 363:2215-2227,

44 Ross OA, Wu YR, Lee MC, Hattori N, Tan EK, Wu RM, et al; Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol. 2008, 64:88-92,

45 Kanai K, Asahina M, Hattori N, Hattori T, et al; Preserved Cardiac I-123-MIBG Uptake and Lack of Severe Autonomic Dysfunction in a PARK9 Patient. ‎Mov Disord, 2009, 24:1403-1405,

46 Nishioka K, Ross OA., Farrer MJ, Hattori N, et al; Expanding the Clinical Phenotype of SNCA Duplication Carriers, Mov Disord, 2009, 24:1811-1819,

47 Mitsui J, Takahashi Y, Hattori N, Tsuji S, et al; Mechanisms of Genomic Instabilities Underlying Two Common Fragile-Site-Associated Loci PARK2 and DMD, in Germ Cell and Cancer Cell Lines, Am J Hum Genet, 2010, 87:75-89,

48 Yoshino H, Tomiyama H, Hattori N, et al; Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism, Neurology, 2010, 75:1356-1361,

49 Funayama M, Tomiyama H, Hattori N, et al; Rapid Screening of ATP13A2 Variant with High-Resolution Melting Analysis, ‎Mov Disord, 2010, 25:2434-37,

50 Saiki S, Sasazawa Y, Hattori N, et al; Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition, Autophagy, 2011, 7:176-187,

51 Ogaki K, Motoi Y, Li Y, Hattori N, et al; Visual Grasping in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (Microtubule-Associated with Protein Tau): A Comparison of N-Isopropyl-p-[I-123]-iodoamphetamine Brain Perfusion Single Photon Emission Computed Tomography Analysis with Progressive Supranuclear Palsy. ‎Mov Disord, 2011, 26:561-563,

52 Ross OA, Soto-Ortolaza AI, Hattori N, Farrer MJ, et al; Genetic Epidemiology Of Parkinson's Disease (GEO-PD) Consortium. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 2011, 10:898-908,

53 Shiba-Fukushima K, Imai Y, Yoshida S, Ishihama Y, Kanao T, Sato S, Hattori N. PINK1-mediated phosphorylation of the Parkin ubiquitin-like domain primes mitochondrial translocation of Parkin and regulates mitophagy, Sci Rep, 2012, 2:1002,

54 Liu S, Sawada T, Hattori N, Imai Y, Lu B, et al; Parkinson's disease-associated kinase PINK1 regulates Miro protein level and axonal transport of mitochondria. PLoS Genet, 2012, 8:e1002537.
55 Funayama M, Yoshino H, Li Y, Kusaka H, Tomiyama H, Hattori N. Pseudo-heterozygous rearrangement mutation of parkin, ‎Mov Disord, 2012, 27:552-555,

55 Sharma M, Ioannidis JP, Hattori N, Krüger R, et al; GEO-PD Consortium. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology. 2012, 79:659-67,

56 Ando M, Funayama M, Li Y, Hattori N, et al; VPS35 mutation in Japanese patients with typical Parkinson's disease, ‎Mov Disord, 2012, 27:1413-1417,

57 Hattori N., Hasegawa K., Sakamoto T. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson's disease, J Clin Pharm Ther, 2012, 37:571-577,

58 Sharma M, Ioannidis JP, Hattori N, Krüger R, et al; GEOPD consortium. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet. 2012, 49:721-6.

59 Itokawa K, Sekine T, Hattori N, Araki N, et al; A case of alpha-synuclein gene duplication presenting with head-shaking movements, ‎Mov Disord, 2013, 28:384-387,

60 Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S. Hattori N. Pilot study of H-2 therapy in Parkinson's disease: A randomized double-blind placebo-controlled trial, Mov Disord, 2013, 28:836-839,

61 Mizuno Y, Nomoto M, Hattori N, et al; Transdermal Rotigotine in Early Stage Parkinson's Disease: A Randomized, Double-blind, Placebo-controlled Trial, Rotigotine Trial Grp, Mov Disord, 2013, 28:1447-1450,

62 Heckman MG, Soto-Ortolaza AI, Hattori N, Ross OA, et al; Genetic Epidemiology of Parkinson's Disease (GEO-PD) Consortium. Population-specific frequencies for LRRK2 susceptibility variants in the Genetic Epidemiology of Parkinson's Disease, Mov Disord. 2013, 28:1740-4.

63 Yamanaka T. Tosaki A, Hattori N, Nukina N, et al; NF-Y inactivation causes atypical neurodegeneration characterized by ubiquitin and p62 accumulation and endoplasmic reticulum disorganization, Nat. Commun, 2014, 5:3354,

64 Miyazaki H, Oyama F, Hattori N, Nukina N, et al; Singular localization of sodium channel beta 4 subunit in unmyelinated fibres and its role in the striatum, Nat Commun. 2014, 5:5525,

65 Hattori N. Cerebral organoids model human brain development and microcephaly, Mov Disord, 2014, 29:185-185,

66 Furuya N, Ikeda SI, Sato S, Hattori N, Ueno T, et al; PARK2/Parkin-mediated mitochondrial clearance contributes to proteasome activation during slow-twitch muscle atrophy via NFE2L1 nuclear translocation, Autophagy, 2014, 10:631-641,

67 Okuzumi A, Hatano T, Nakahara T, Yokoyama K, Hattori N. Ophthalmic nerve hypertrophy in chronic inflammatory demyelinating polyradiculoneuropathy, Neurology, 2014, 82:1566-1567,

68 Hattori N. REST as a New Therapeutic Target for Neurodegenerative Disorders, Mov Disord, 2014, 29:869-869,

69 Maraschi A, Ciammola A, Sato S, Hattori N, Sassone J, et al; Parkin regulates kainate receptors by interacting with the GluK2 subunit. Nat Commun, 2014, 5:5182.

70 Kurosawa M, Matsumoto G, Hattori N, Nukina N, et al; Depletion of p62 reduces nuclear inclusions and paradoxically ameliorates disease phenotypes in Huntington's model mice, Hum Mol Gen, 2015, 24:1092-1105,

71 Matsuo H, Tomiyama H, Hattori N, Shinomiya N, et al; ABCG2 variant has opposing effects on onset ages of Parkinson's disease and gout, Ann Clin Transl Neurol, 2015, 2:302-306,

72 Variants associated with Gaucher disease in multiple system atrophy. Ann Clin Transl Neurol. 2015, 2:417-26.

73 Matsumoto G, Shimogori T, Hattori N, Nukina N. TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation, Hum Mol Gen, 2015, 24:4429-4442,

74 Imai Y, Kobayashi Y, Nukina N. Hattori N, Takahashi R, et al; The Parkinson's Disease-Associated Protein Kinase LRRK2 Modulates Notch Signaling through the Endosomal Pathway, PLoS Genet, 2015,11:e1005503,

75 Wang L, Aasly JO, Hattori N, Sharma M, et al; GEO-PD Consortium. Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85:1283-1292,

76 Ogaki K, Koga S, Hattori N, Ross OA, et al; Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders, Neurology, 2015, 85:2016-25,

77 Hatano T, Kurita N, Kobayashi M, Hattori N. Teaching Video NeuroImages: Re-emergent jaw tremor in Parkinson disease. Neurology, 2015, 85:e181,

78 Takanashi M, Li Y, Hattori N. Absence of Lewy pathology associated with PINK1 homozygous mutation, Neurology, 2016, 86:2212-2213,

79 Kamagata K, Hatano T, Okuzumi A, Motoi Y, Abe O, Shimoji K, Kamiya K, Suzuki M, Hori M, Kumamaru K, Hattori N, Aoki S. Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease, Euro Radiol, 2016, 26:2567-2577,

80 Sato S, Koike M, Funayama M, Ezaki J, Fukuda T, Ueno T, Uchiyama Y, Hattori N. Lysosomal Storage of Subunit c of Mitochondrial ATP Synthase in Brain-Specific Atp13a2-Deficient Mice, Am J Pathol, 2016, 186:3074-3082,

81 Matsushima T, Conedera S, Tanaka R, Li Y, Yoshino H, Funayama M, Ikeda A, Hosaka Y, Okuzumi A, Shimada Y, Yamashiro K, Motoi Y, Nishioka K, Hattori N. Genotype-phenotype correlations of cysteine replacement in CADASIL, Neurobiol. Aging, 2017, 50:169.e7,

81 Inoshita T, Arano T, Hosaka Y, Meng H, Umezaki Y, Kosugi S, Morimoto T, Koike M, Chang H-Y, Imai Y, Hattori N. Vps35 in cooperation with LRRK2 regulates synaptic vesicle endocytosis through the endosomal pathway in Drosophila, Hum Mol Genet, 2017, 26:2933-2948,

82 Shiba-Fukushima K, Ishikawa KI, Inoshita T, Izawa N, Takanashi M, Sato S, Onodera O, Akamatsu W, Okano H, Imai Y, Hattori N. Evidence that phosphorylated ubiquitin signaling is involved in the etiology of Parkinson's disease. Hum Mol Genet. 2017, 26(16):3172-3185.

83 Saiki S, Hatano T, Fujimaki M, Ishikawa KI, Mori A, Oji Y, Okuzumi A, Fukuhara T, Koinuma T, Imamichi Y, Nagumo M, Furuya N, Nojiri S, Amo T, Yamashiro K, Hattori N. Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease. Sci Rep. 2017 Aug 4;7(1):7328.　

84 Hattori N, Arano T, Hatano T, Mori A, Imai Y. Mitochondrial-Associated Membranes in Parkinson's Disease. Adv Exp Med Biol. 2017;997:157-169.

85 Hattori N, Mizuno Y. Twenty years since the discovery of the parkin gene. J Neural Transm (Vienna). 2017 Sep; 124(9):1037-1054

86 Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa KI, Kobayashi K, Murayama S, Hwang SH, Saiki S, Akamatsu W, Hattori N, Hammock BD, Hashimoto K. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5815-E5823.

87 Taniguchi D, Hatano T, Kamagata K, Okuzumi A, Oji Y, Mori A, Hori M, Aoki S, Hattori N. Neuromelanin imaging and midbrain volumetry in progressive supranuclear palsy and Parkinson's disease. Mov Disord. 2018 Sep;33(9):1488-1492.

88 Yoritaka A, Ohtsuka C, Maeda T, Hirayama M, Abe T, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Oda E, Ito M, Ohno K, Hattori N. Randomized, double-blind, multicenter trial of hydrogen water for Parkinson's disease. Mov Disord. 2018 Sep;33(9):1505-1507.

89 Fujimaki M, Saiki S, Li Y, Kaga N, Taka H, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Koinuma T, Ueno SI, Imamichi Y, Ueno T, Miura Y, Funayama M, Hattori N. Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease. Neurology. 2018 Jan 30;90(5):e404-e411.

90 Mishima T, Fujioka S, Tomiyama H, Yabe I, Kurisaki R, Fujii N, Neshige R, Ross OA, Farrer MJ, Dickson DW, Wszolek ZK, Hattori N, Tsuboi Y. Establishing diagnostic criteria for Perry syndrome. J Neurol Neurosurg Psychiatry. 2018 May;89(5):482-487.

91 Takanashi M, Funayama M, Matsuura E, Yoshino H, Li Y, Tsuyama S, Takashima H, Nishioka K, Hattori N. Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutations. Acta Neuropathol Commun. 2018 Oct 17;6(1):105.

92 Sato S, Uchihara T, Fukuda T, Noda S, Kondo H, Saiki S, Komatsu M, Uchiyama Y, Tanaka K, Hattori N. Loss of autophagy in dopaminergic neurons causes Lewy pathology and motor dysfunction in aged mice. Sci Rep. 2018 Feb 12;8(1):2813.

93 Ueno SI, Saiki S, Fujimaki M, Takeshige-Amano H, Hatano T, Oyama G, Ishikawa KI, Yamaguchi A, Nojiri S, Akamatsu W, Hattori N. Zonisamide Administration Improves Fatty Acid β-Oxidation in Parkinson's Disease. Cells. 2018 Dec 29;8(1). pii: E14.

94 Ikeda A, Shimada H, Nishioka K, Takanashi M, Hayashida A, Li Y, Yoshino H, Funayama M, Ueno Y, Hatano T, Sahara N, Suhara T, Higuchi M, Hattori N. Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features. Mov Disord. 2019 Apr;34(4):568-574.

95 Okuzumi A, Hatano T, Kamagata K, Hori M, Mori A, Oji Y, Taniguchi D, Daida K, Shimo Y, Yanagisawa N, Nojiri S, Aoki S, Hattori N. Neuromelanin or DaT-SPECT: which is the better marker for discriminating advanced Parkinson's disease? Eur J Neurol. 2019 Nov;26(11):1408-1416.

96 Imai Y, Inoshita T, Meng H, Shiba-Fukushima K, Hara KY, Sawamura N, Hattori N. Light-driven activation of mitochondrial proton-motive force improves motor behaviors in a Drosophila model of Parkinson's disease. Commun Biol. 2019 Nov 22;2:424,

97 Ikeda A, Nishioka K, Meng H, Takanashi M, Hasegawa I, Inoshita T, Shiba-Fukushima K, Li Y, Yoshino H, Mori A, Okuzumi A, Yamaguchi A, Nonaka R, Izawa N, Ishikawa KI, Saiki H, Morita M, Hasegawa M, Hasegawa K, Elahi M, Funayama M, Okano H, Akamatsu W, Imai Y, Hattori N. Mutations in CHCHD2 cause α-synuclein aggregation. Hum Mol Genet. 2019 Dec 1;28(23):3895-3911.

98 Ogawa T, Hatano T, Oyama G, Takanashi M, Taniguchi D, Hattori N. Graphic Summary of Movement Disorders Society Criteria for Progressive Supranuclear Palsy and Multiple Allocations eXtinction Rules. Mov Disord Clin Pract. 2020 Jan 20;7(2):240-242.

99 Miyamoto N, Magami S, Inaba T, Ueno Y, Hira K, Kijima C, Nakajima S, Yamashiro K, Urabe T, Hattori N. The effects of A1/A2 astrocytes on oligodendrocyte linage cells against white matter injury under prolonged cerebral hypoperfusion. Glia. 2020 Sep;68(9):1910-1924.

100 Hattori N, Mochizuki H, Hasegawa K, Nomoto M, Uchida E, Terahara T, Okawa K, Fukuta H. Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease. Mov Disord. 2020 Sep;35(9):1565-1573.

101 Li Y, Ikeda A, Yoshino H, Oyama G, Kitani M, Daida K, Hayashida A, Ogaki K, Yoshida K, Kimura T, Nakayama Y, Ito H, Sugeno N, Aoki M, Miyajima H, Kimura K, Ueda N, Watanabe M, Urabe T, Takanashi M, Funayama M, Nishioka K, Hattori N. Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. J Hum Genet. 2020 Sep;65(9):771-781.

102 Takeshige-Amano H, Saiki S, Fujimaki M, Ueno SI, Li Y, Hatano T, Ishikawa KI, Oji Y, Mori A, Okuzumi A, Tsunemi T, Daida K, Ishiguro Y, Imamichi Y, Nanmo H, Nojiri S, Funayama M, Hattori N. Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. Mov Disord. 2020 Aug;35(8):1438-1447.

103 Hattori N, Kitabayashi H, Kanda T, Nomura T, Toyama K, Mori A. A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease. Mov Disord. 2020 Aug;35(8):1481-1487,

104 Daida K, Nishioka K, Li Y, Yoshino H, Shimada T, Dougu N, Nakatsuji Y, Ohara S, Hashimoto T, Okiyama R, Yokochi F, Suzuki C, Tomiyama M, Kimura K, Ueda N, Tanaka F, Yamada H, Fujioka S, Tsuboi Y, Uozumi T, Takei T, Matsuzaki S, Shibasaki M, Kashihara K, Kurisaki R, Yamashita T, Fujita N, Hirata Y, Ii Y, Wada C, Eura N, Sugie K, Higuchi Y, Kojima F, Imai H, Noda K, Shimo Y, Funayama M, Hattori N. PLA2G6 variants associated with the number of affected alleles in Parkinson's disease in Japan. Neurobiol Aging. 2021 Jan;97:147.e1-147.e9.

105 Andica C, Kamagata K, Saito Y, Uchida W, Fujita S, Hagiwara A, Akashi T, Wada A, Ogawa T, Hatano T, Hattori N, Aoki S. Fiber-specific white matter alterations in early-stage tremor-dominant Parkinson's disease. NPJ Parkinsons Dis. 2021 Jun 25;7(1):51.

106 Elahi M, Motoi Y, Shimonaka S, Ishida Y, Hioki H, Takanashi M, Ishiguro K, Imai Y, Hattori N. High-fat diet-induced activation of SGK1 promotes Alzheimer's disease-associated tau pathology. Hum Mol Genet. 2021 Aug 28;30(18):1693-1710.

107 Kataura T, Tashiro E, Nishikawa S, Shibahara K, Muraoka Y, Miura M, Sakai S, Katoh N, Totsuka M, Onodera M, Shin-Ya K, Miyamoto K, Sasazawa Y, Hattori N, Saiki S, Imoto M. A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers. Autophagy. 2021 Aug;17(8):1856-1872.

108 Okuzumi A, Hatano T, Fukuhara T, Ueno S, Nukina N, Imai Y, Hattori N. α-Synuclein Seeding Assay Using RT-QuIC. Methods Mol Biol. 2021;2322:3-16.

109 Tsunemi T, Ishiguro Y, Yoroisaka A, Hattori N. Analysis of α-Synuclein in Exosomes. Methods Mol Biol. 2021;2322:41-45.
Tsunemi T, Oyama G, Saiki S, Hatano T, Fukae J, Shimo Y, Hattori N. Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review. Mov Disord. 2021 Aug;36(8):1759-1771.
110

--

研究者

教育活動

ホームページURL

【学校法人順天堂】研究者情報データベース

研究業績詳細

服部 信孝（ハットリ ノブタカ）

服部信孝（ハットリノブタカ）